Compare Quest Diagnostics Inc (DGX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Quest Diagnostics Inc trades at $202.3 (market cap $22.80B), while State Street Real Estate Select Sector SPDR ETF trades at $44.56. The key difference: Quest Diagnostics Inc pays a 1.67% dividend while State Street Real Estate Select Sector SPDR ETF pays none, and State Street Real Estate Select Sector SPDR ETF is trading nearer its 52-week high, Quest Diagnostics Inc nearer its low. Which is the better fit depends on your goals.
| DGX | XLRE | |
|---|---|---|
Market Cap | $22.80B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.02 | $45.36 |
52-Week Low | $166.45 | $40.01 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
XLRE, the Real Estate Select Sector SPDR ETF, trades at $44.70 with a 0.56% daily gain, reflecting positive momentum amid a broader real estate sector recovery. Technical indicators show a bullish moving average consensus while oscillators remain neutral. The ETF's low 0.08% expense ratio and 3.4% dividend yield provide cost-efficient real estate exposure. Recent news highlights REITs defying rate pressures with strong 2026 performance, though inflation and Treasury yield volatility remain headwinds.
The outlook for XLRE appears cautiously optimistic as real estate fundamentals improve with steady NOI growth and declining supply. Key opportunities include attractive valuations and potential rate stability, while risks center on interest rate sensitivity and economic slowdowns. With technical strength and sector tailwinds, XLRE offers diversified real estate exposure but requires monitoring of Federal Reserve policy shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
